AI supercomputer decodes protein language, aids cancer research

IKZF2, also known as Helios, is a critical zinc-finger transcription factor that plays a vital role in sustaining immune system balance. The compound DKY709 exhibits notable anti-cancer effects by interacting with Cereblon (CRBN), a protein that modifies its structure to promote the binding and subsequent degradation of IKZF2. This mechanism highlights DKY709's potential in cancer therapy by targeting and disrupting specific molecular pathways. Such insights are crucial for advancing our understanding of cancer biology and developing innovative treatments. #ImmunoOncology #MolecularTherapeutics #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #DrugTargeting #ChallengingTarget #DrugTarget #BiotechInnovation #TherapeuticDiscovery #BiomedicalInnovation #CellarisBio #DEL #Biotech #Pharma #BiotechAdvancements #PrecisionMedicine #BiotechInnovation

A clinical-stage biotech developing a therapy for a difficult-to-treat cancer hit a wall. Their bottom-up proteomics approach couldn’t detect the key modification needed to validate the drug’s mechanism of action—stalling development and delaying critical milestones Using intact proteoform analysis, ImmPro confirmed the drug's mechanism of action and uncovered a new proteoform that could guide patient stratification. Download the case study to learn more: https://lnkd.in/gQNdMtdA

#FRET in complex conditions - Post translational protein modification QF-Pro is useful to see biomarker interactions in complex tissue conditions. Very often we're looking at biomarker interactions in cancer patients, but scientist at HAWK Biosystems have also used it to track post-translational changes in proteins. The QF-Pro score clearly tracks phosphorylation of Akt/PKB peaking at 10' showing the dynamic activation with high temporal resolution. #biomarkers #proteomics #FRET #QFPro #EGF #Akt

Excited to share the launch of our 𝐏𝟐-𝐢𝐒𝐓 for Plasma proteomics, a joint innovation by PreOmics and Biognosys! This combined solution brings together the unique P2 enrichment technology with the advanced sample preparation iST kit to unlock deeper insights into the plasma proteome with thousands of proteins. Proud of the collaboration and the impact this will have on accelerating biomarker discovery for diseases and drugs, supporting clinical trials and many more. With a wealth of information on PTMs and proteoforms. Launched now at HUPO 2025! #proteomics #oncology #cancer #clinicaltrial #biomarker #proteoform #HUPO #plasma

Lamassu Biotech today announced a significant clinical milestone in its Phase 1/2a trial investigating SA53, a first-in-class, small-molecule MDM2 inhibitor. According to data reviewed to date, there have been no serious or dose limiting adverse events, and SA53 has thus far demonstrated a favorable safety and tolerability profile. The therapy is currently advancing into higher-dose cohorts for the treatment of adult patients with solid tumors. The ongoing Phase 1/2a trial, conducted in collaboration with the National Institutes of Health and Cleveland Clinic, is designed to determine the safety, tolerability, pharmacokinetics, and preliminary efficacy of SA53. The therapy is being investigated in adult patients with sarcoma and other solid tumors who possess the p53 wild-type gene and who currently have limited therapeutic options. Read the full announcement here: https://lnkd.in/ePTjXt9U #biotech #healthcare #medicine #research #Cancer #cancertreatment

Speed + accuracy = smarter sequencing Konstantin Fiedler from Integrated DNA Technologies shares how labs can balance rapid results with reliable data using customizable Archer™ NGS Assays. From tackling degraded cancer samples to streamlining entire workflows, discover how IDT is helping scientists achieve faster, more confident insights in oncology research. Read his insights here: https://bit.ly/485eBU6

Antibody-drug conjugates (ADCs) are a step forward in providing advanced cancer therapies to patients. Mastering the technology to produce them at commercial scale requires expertise and skills. At Boehringer Ingelheim, we’re moving beyond traditional cell-based methods to manufacture the underlying antibody. This makes it possible to reliably produce significant amounts of innovative ADCs – with greater consistency and speed.   ❓ Curious how this technology works and what it means for the future of cancer care? ➡️ Read the full story in the whitepaper on our website: https://lnkd.in/eQkdRBT9   #LifeForward #Biotechnology #ManufacturingTechnology

We are excited to collaborate with Boehringer Ingelheim on this insightful whitepaper – “Advancing Cell-Free Antibody-Drug Conjugate (ADC) Manufacturing for Better Patient Outcomes.” For more info: https://lnkd.in/gF5PHkwy #SutroBio #BI #LifeForward #ManufacturingTechnology #BiotechNews

Cell-free ADC manufacturing is here. Sutro Biopharma and Boehringer Ingelheim just proved it can be done — commercial scale, consistent quality, real impact. For PK and bioanalytical scientists, this is transformative: ✅ Cleaner data ✅ Consistent DAR and conjugation sites ✅ Faster molecule turnaround Innovation like this turns ADC development from art into engineered precision — and makes our work that much more rewarding.

👀 GPERs Creepers: When Estrogen Signals Get Spooky “GPERs creepers, where’d you get those signals?” 🎶 If you know about G protein-coupled receptors (GPCRs), you know they’re EVERYWHERE.  They orchestrate how cells sense hormones, neurotransmitters, and environmental cues. One member of this protein family has been stirring up cancer research: GPER, the G protein-coupled estrogen receptor. When GPER is activated, it sets off fast, non-genomic estrogen signaling that can drive tumor growth, invasion, and even resistance to therapy. In short, when GPER gets active, cancer cells can start to behave a little… creepy. 🧫 That’s where Sandia Biotech’s GPER agonist (G1) and antagonists (G15 & G36) come in. These research tools help scientists turn GPER “on” or “off” with precision, mapping how this receptor influences signaling pathways or how it shapes the tumor microenvironment. This spooky season, keep an eye on those GPERs… they might reveal the next big clue in cancer signaling. 🔬 Explore Sandia Biotech’s GPER agonist and antagonist reagents. #GPCR #GPER #CancerResearch #Biotech #MolecularOncology